Your browser is no longer supported. Please, upgrade your browser.
ETTX Entasis Therapeutics Holdings Inc. monthly Stock Chart
Entasis Therapeutics Holdings Inc.
Index- P/E- EPS (ttm)-3.36 Insider Own52.60% Shs Outstand29.96M Perf Week-2.76%
Market Cap62.43M Forward P/E- EPS next Y-1.23 Insider Trans- Shs Float13.57M Perf Month7.32%
Income-53.80M PEG- EPS next Q-0.39 Inst Own30.90% Short Float0.83% Perf Quarter-32.57%
Sales0.00M P/S- EPS this Y-3.50% Inst Trans27.25% Short Ratio0.23 Perf Half Y-35.06%
Book/sh2.08 P/B0.85 EPS next Y49.00% ROA-101.50% Target Price- Perf Year-62.87%
Cash/sh- P/C- EPS next 5Y- ROE-118.70% 52W Range1.58 - 5.64 Perf YTD-64.59%
Dividend- P/FCF- EPS past 5Y- ROI-112.80% 52W High-68.79% Beta-
Dividend %- Quick Ratio10.00 Sales past 5Y- Gross Margin- 52W Low11.39% ATR0.08
Employees47 Current Ratio10.00 Sales Q/Q- Oper. Margin- RSI (14)46.04 Volatility3.71% 4.22%
OptionableNo Debt/Eq0.00 EPS Q/Q-40.00% Profit Margin- Rel Volume1.13 Prev Close1.77
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume496.66K Price1.76
Recom1.90 SMA202.15% SMA50-11.11% SMA200-37.58% Volume563,412 Change-0.56%
Sep-09-20Initiated Cantor Fitzgerald Overweight $5
Jul-13-20Initiated ROTH Capital Buy $9
Nov-17-20 08:00AM  
Nov-05-20 04:05PM  
Oct-14-20 08:00AM  
Oct-08-20 08:32AM  
Sep-10-20 08:00AM  
Aug-28-20 08:00AM  
Aug-06-20 04:05PM  
Aug-05-20 08:00AM  
Jul-13-20 10:05AM  
Jul-06-20 08:00AM  
Jun-22-20 09:48AM  
Jun-18-20 08:00AM  
Jun-11-20 04:05PM  
May-18-20 11:34AM  
May-07-20 04:05PM  
Apr-22-20 04:05PM  
Mar-13-20 07:46AM  
Mar-11-20 04:05PM  
Dec-19-19 09:49AM  
Nov-24-19 01:56PM  
Nov-14-19 07:30AM  
Oct-30-19 04:05PM  
Oct-29-19 08:30AM  
Oct-03-19 04:01PM  
Oct-01-19 10:07AM  
Sep-30-19 01:00AM  
Sep-19-19 11:56AM  
Sep-03-19 08:00AM  
Aug-12-19 07:30AM  
Aug-06-19 08:00AM  
Jul-01-19 09:13AM  
Jun-27-19 08:00AM  
Jun-24-19 08:00AM  
Jun-20-19 11:13AM  
Jun-18-19 04:01PM  
Jun-13-19 08:00AM  
Jun-10-19 08:00AM  
Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel antibacterial products to treat serious infections caused by multi-drug resistant gram-negative bacteria in the United States. It is involved in developing Sulbactam-durlobactam (SUL-DUR), a novel IV antibiotic that has completed Phase II clinical trial for the treatment of multi-drug resistant Acinetobacter infections; Zoliflodacin, a novel orally administered molecule that has completed Phase II clinical trial for the treatment of uncomplicated gonorrhea; ETX0282CPDP, an oral drug that is in Phase I clinical trial for the treatment of urinary tract infections; and ETX0462, a drug candidate from NBP platform that is in pre-clinical stage for the treatment of multidrug-resistant Gram-negative infections. The company has collaboration agreements with Zai Lab (Shanghai) Co., Ltd. for developing SUL-DUR. Entasis Therapeutics Holdings Inc. was incorporated in 2018 and is based in Waltham, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Innoviva, Inc.10% OwnerSep 01Buy2.684,672,89712,499,99918,672,897Sep 01 05:31 PM
Innoviva, Inc.10% OwnerJun 11Buy2.5012,677,49031,693,72514,000,000Jun 12 05:34 PM
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 All Rights Reserved.